


amazon.in/Textbook-Pharmacology-Bhandari/dp/9390553156



Prasan R. Bhandari

See this image

Follow the Author

Prasan R Bhandari Follow

Kindle Edition ₹3,318.19

Paperback ₹1,100.00

Read with Our **Free App** 8 New from ₹1,100.00

EMI starts at ₹376 per month. EMI options

Save Extra with 4 offers

No Cost EMI: Avail No Cost EMI on select cards for orders above ₹3000 | [Details](#)

Bank Offer (2): 5% Instant Discount up to INR 250 on HSBC Cashback Card Credit Card Transactions. Minimum purchase value INR 1000 | [See All](#)

See 2 more

Free Delivery

10 days Replacement

Amazon Delivered

Secure transaction

Save up to 2% with business pricing and GST input tax credit. [Sign up for a free Amazon Business account](#)

The revision of the Indian medical curriculum in 2018 put an emphasis on learner-centered, integrated, and competency-based learning. This is meant to facilitate the acquisition of skills along with ethical and humanistic values. The revised curriculum for undergraduate medical education enables the Indian medical graduate to recognize "Health for All" as a national goal and fulfill their societal obligations. The curriculum in pharmacology is witnessing a sea change from emphasis on animal experiments and dispensing pharmacy-based curriculum to an "applied" approach, where the emphasis is on how the student prescribes rationally, taking into view the various facets of the medicine and the patient. All competencies as per the new curriculum of the National

[Read more](#)

[Report incorrect product information.](#)

ISBN-10	ISBN-13	Edition	Publisher	Publication date	Language
9390553156	978-9390553150	# First	Thieme Publishers	1 December 2021	English

FREE delivery Friday, 5 May. Order within 1 hr 27 mins. [Details](#)

Deliver to vivek - Udaipur 313002

In stock

Sold by **BOOKS & EQUIPMENT DISTRIBUTORS** and Delivered by Amazon.

Quantity:

[Add to Cart](#)

[Buy Now](#)

Secure transaction

[Add to Wish List](#)

Buy it on Amazon Business

Save up to 2% on this product with business pricing and GST input tax credit

[Create a free account](#)

The Top 100 Drugs: Clinical Pharmacology...

★★★★★ 1,028

₹2,202.00 [prime](#)

Sponsored

Have one to sell?

Contents

Foreword	xiii
Preface	xv
Acknowledgments	xvii
Contributors	xix
Competency Mapping Chart	xxvii

Part I: General Pharmacology

1. Definitions and Sources of Drugs <i>Madhura Bhosale and Prachitee Borkar</i>	2
2. Routes of Drug Administration <i>Madhura Bhosale and Prachitee Borkar</i>	4
3. Pharmacokinetics <i>Ramanand Patil</i>	8
4. Pharmacodynamics <i>Shraddha Yadav and Prasan R. Bhandari</i>	17
5. Drug Interactions <i>Mayank Kulshreshtha, Shivam Yadav, and Prasan R. Bhandari</i>	37
6. Adverse Drug Reactions and Its Monitoring and Pharmacovigilance <i>Viraj A. Shinde and Ramanand Patil</i>	41
7. Occupational and Environmental Pesticides, Food Adulterants, and Insect Repellents <i>Manjunath G.N. and Swamy R. M.</i>	45
8. Management of Common Poisonings, Insecticides, and Common Stings and Bites <i>Sri H. Thakkalapally</i>	51
9. New Drug Approval Process and Clinical Trials <i>Viraj A. Shinde</i>	63
10. Pharmacogenomics and Pharmacoeconomics <i>Manju Agrawal</i>	66
11. Dietary Supplements and Nutraceuticals <i>Prasan R. Bhandari</i>	76
12. Drug Regulations, Acts, and Other Legal Aspects <i>Prasan R. Bhandari</i>	79
13. Prescription Writing <i>Prachitee Borkar and Viraj A. Shinde</i>	82
14. Basic Aspects of Geriatric and Pediatric Pharmacology <i>M. Vijay Kumar</i>	87

-
15. National Health Programme 91
M. Vijay Kumar

Part II: Drugs Affecting Autonomic Nervous System

16. Introduction to the Nervous System 104
D. H. Nandal, Sandeep Prakash Narwane, and Rashmi Bhaskarrao Kharde
17. Cholinergic System 110
Prasan R. Bhandari
18. Anticholinergics, Atropine, and Its Substitutes 119
Mayank Kulshreshtha, Rajaneesh Kumar Chaudhary, and Swetza Singh
19. Skeletal Muscle Relaxants 123
Farhana Rahman
20. Adrenergic System and Adrenergic Drugs 131
Prasan R. Bhandari
21. Adrenergic Receptor Blockers 139
Shardendu Kumar Mishra

Part III: Drugs Affecting Cardiovascular System

22. Renin–Angiotensin System 148
Shubhadeep Sinha, Leela Talluri, and Prasan R. Bhandari
23. Congestive Cardiac Failure 155
Vishal Munjajirao Ubale
24. Antianginals and Drug Treatment of Myocardial Infarction—1 167
Nishigandha Suresh Jadhav
25. Antianginals and Drug Treatment of Myocardial Infarction—2 175
Upinder Kaur and Sankha Shubhra Chakrabarti
26. Antihypertensives 187
Prasan R. Bhandari
27. Pharmacotherapy of Shock 204
D. Thamizh Vani and Dipti Sonawane
28. Antiarrhythmic Drugs 210
Vivek Jain

Part IV: Renal Pharmacology

29. Diuretics and Antidiuretics 226
Prasan R. Bhandari

Part V: Drugs Affecting Central Nervous System

30. Introduction to CNS 236
Anuja Jha

31.	General Anesthetics <i>Areeg Anwer Ali and Bhoomendra A. Bhongade</i>	238
32.	Local Anesthetics <i>Areeg Anwer Ali and Syed Ayaz Ali</i>	254
33.	Sedatives and Hypnotics <i>Panini Patankar and Nishtha Khatri</i>	267
34.	Alcohol <i>Tithishri Kundu</i>	278
35.	Antiepileptic Drugs <i>A. Meenakumari</i>	288
36.	AntiParkinsonian Drugs and Drugs for Treatment of Alzheimer's Disease <i>Veena R.M., Manisha Prajapat, Jitupam Baishya, Harpinder Kaur, Phulen Sarma, and Bikash Medhi</i>	301
37.	CNS Stimulants and Drugs of Abuse <i>Anupam Raja, Harvinder Singh, Harish Kumar, Phulen Sarma, Ajay Prakash, and Bikash Medhi</i>	316
38.	Antidepressants and Mood Stabilizers <i>Shailesh Bhosle, Biplob Sikdar, and Awanish Mishra</i>	327
39.	Antipsychotic Drugs <i>Nishigandha Suresh Jadhav</i>	342
40.	Opioid Analgesics <i>Ramanand Patil</i>	354

Part VI: Autacoids

41.	Histamine and Antihistaminics <i>Jameel Ahmad, Bushra Hasan Khan, and Prerna Singh</i>	360
42.	Serotonin (5-Hydroxytryptamine) Agonists and Antagonists, Ergot Alkaloids, and Drug Treatment of Migraine <i>Nishita H. Darji, Suhani V. Patel, and Vishalkumar K. Vadgama</i>	370
43.	Eicosanoids–Prostaglandins, Thromboxanes, and Leukotrienes <i>Vishalkumar K. Vadgama</i>	386
44.	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) <i>Satish Eknath Bahekar</i>	399
45.	Rheumatoid Arthritis and Gout <i>Suneha Sikha</i>	408

Part VII: Drugs Used in Respiratory System

46.	Pharmacotherapy of Bronchial Asthma <i>Farhana Dutta Majumder</i>	422
47.	Drugs for Treatment of Cough <i>Farhana Dutta Majumder</i>	431

Part VIII: Drugs Acting on Blood and Blood-forming Organs

- | | | |
|-----|--|-----|
| 48. | Hematinics and Treatment of Anemia
<i>Shikha Jaiswal Shivhare</i> | 438 |
| 49. | Coagulants and Anticoagulants
<i>Tejus A.</i> | 444 |
| 50. | Drugs Used in Dyslipidemias
<i>Shraddha M. Pore</i> | 461 |

Part IX: Drugs Affecting Gastrointestinal System

- | | | |
|-----|--|-----|
| 51. | Antiplatelet and Thrombolytic Drugs
<i>Upinder Kaur and Sankha Shubhra Chakrabarti</i> | 470 |
| 52. | Drug Therapy of Peptic Ulcer and Gastroesophageal Reflux Disease
<i>Harpinder Kaur, Phulen Sarma, Bikash Medhi, and Chandra Das</i> | 475 |
| 53. | Pharmacotherapy of Nausea and Vomiting
<i>Arulmozhi S. and Saieswari Natesan</i> | 485 |
| 54. | Drug Treatment of Diarrhea
<i>Vetriselvan Subramanian, Neeraj Kumar Fuloria, Shivkanya Fuloria, and Iswar Hazarika</i> | 493 |
| 55. | Drug Treatment for Constipation and IBD
<i>Prasan R. Bhandari</i> | 497 |

Part X: Chemotherapy

- | | | |
|------|--|-----|
| 56. | General Considerations
<i>Shruti Chandra</i> | 504 |
| 57. | Sulfonamides and Cotrimoxazole
<i>Prasan R. Bhandari</i> | 519 |
| 58. | Fluoroquinolones
<i>Shweta Sinha</i> | 527 |
| 59A. | Penicillin
<i>Shantanu R. Joshi</i> | 532 |
| 59B. | Cephalosporins
<i>Sonali Karekar</i> | 545 |
| 60. | Broad-Spectrum Antibiotics
<i>Prasan R. Bhandari</i> | 552 |
| 61. | Aminoglycosides
<i>D. Thamizh Vani</i> | 557 |
| 62. | Macrolides and Miscellaneous Antimicrobials and Pharmacotherapy of STD and UTI
<i>Asha B.</i> | 560 |
| 63. | Antituberculosis Drugs
<i>Jitendra H. Vaghela</i> | 570 |

64.	Chemotherapy of Leprosy <i>Prasan R. Bhandari</i>	579
65.	Antifungal Agents <i>Amrita Sil</i>	582
66.	Antiviral Drugs <i>Niti Mittal and Jitendra H. Vaghela</i>	590
67.	Chemotherapy of Malaria <i>Prasan R. Bhandari</i>	605
68.	Antiamebics and Drugs for Leishmaniasis, Trypanosomiasis, and Pneumocystosis <i>Anuja Jha and Prasan R. Bhandari</i>	613
69.	Anthelmintic Drugs <i>Alka Bansal</i>	618
70.	Cancer Chemotherapy <i>C. S. Suthakaran and Prasan R. Bhandari</i>	627
71.	Antimicrobial Stewardship <i>Vasudeva Murthy, T. Smitha, and Asha B.</i>	636

Part XI: Endocrine Pharmacology

72.	Hypothalamic and Anterior Pituitary Hormones <i>Arunachalam Muthuraman, Aswinprakash Subramanian, and Jagadeesh Dhamodharan</i>	648
73.	Thyroid Hormones and Antithyroid Drugs <i>Kiran Rajendra Giri, Kamlesh M. Palandurkar, and Reena Rajendra Giri</i>	667
74.	Pharmacology of Estrogens and Related Drugs <i>Sheshidhar Bannale</i>	675
75.	Androgens and Anabolic Steroids <i>Upinder Kaur and Amit Singh</i>	684
76.	Drugs for Erectile Dysfunction <i>Upinder Kaur and Sankha Shubhra Chakrabarti</i>	690
77.	Antidiabetic Drugs <i>Yogesh A. Kulkarni</i>	695
78.	Corticosteroids <i>Prasan R. Bhandari</i>	710
79.	Agents Affecting Calcium Balance <i>Janakidevi C. H.</i>	725
80.	Drugs Acting on the Uterus: Oxytocics and Tocolytics <i>Vaishali Undale</i>	733

Part XII: Miscellaneous

81.	Chelating Agents and Heavy Metal Poisoning <i>Rupali A. Patil, Shubhangi H. Pawar, Sunil V. Amrutkar, and Rajendra S. Bhambar</i>	742
-----	--	-----

82.	Immunosuppressants and Stimulants	752
	<i>Prince Allawadhi, Sachin Karkale, Amit Khurana, and Kala Kumar Bharani</i>	
83.	Vaccines and Sera	764
	<i>Arshiya Sehgal and Vijay Kumar Sehgal</i>	
84.	Antioxidants	774
	<i>Tuhin Kanti Biswas, Mayank Kulshreshtha, and Shivam Yadav</i>	
85.	Physiological Functions of Essential Bioelements in Humans	783
	<i>Srinivasa Reddy Yathapu, Narendrababu Kondapalli, and B. Dinesh Kumar</i>	
86.	Minerals	788
	<i>Arpita Shrivastav and Neeraj Shrivastav</i>	
87.	Dermatopharmacology	792
	<i>Rahul Kumar and Vinita Awasthi</i>	
88.	Gene Therapy	800
	<i>Nilofer Sayed, Prince Allawadhi, Amit Khurana, and Kala Kumar Bharani</i>	
89.	Antiseptics and Disinfectants	806
	<i>Vijayakumar AE</i>	
90.	Drug Therapy of Medical Emergencies	811
	<i>Snehal Lonare and Prasan R. Bhandari</i>	
91.	Drugs Used in Ocular Disorders	813
	<i>Shrikant V. Joshi and Sapna D. Desai</i>	
92.	Essential Medicines, Fixed-Dose Combinations, Over-the-Counter Drugs, and Herbal Medicine	837
	<i>R. Srinivasa Rao</i>	
	Index	845

Chapter 28

Antiarrhythmic Drugs

Vivek Jain

PH1.30: Describe the mechanisms of action, types, doses, side effects, indications, and contraindications of the antiarrhythmics.

Learning Objectives

- Cardiac arrhythmias.
- Cardiac action potential.
- Classification of arrhythmia:
 - Class I drugs.
 - Class ID (miscellaneous).
 - Class II agents.
 - Class III agents.
 - Class IV agents.

Cardiac Arrhythmia

A healthy human heart always beats with its own rhythm, which originates from the autorhythmic fibers of the right atrium called sinoatrial (SA) node. For the patient and physician, the heart rhythm serves as an indicator of well-being and disease. When the heart rhythm is disrupted due to ischemia, sympathetic stimulation, myocardial scarring, inherited variation in ion channel or other genes, and ingestion of drugs that affect heart conduction, it may result in cardiac arrhythmia. The clinical signs of cardiac arrhythmia are strong or fast heartbeat (palpitations), fluttering, dizziness, drowsiness, shortness of breath, tiredness, lack of energy, major discomfort when exercising, near-fainting, fainting, and chest pain.

Cardiac Action Potential

The resting membrane potential of the myocardium is approximately -90 mV, which results from an unequal distribution of ions (high Na^+ outside, high K^+ inside). There are five phases of the cardiac action potential (AP) (Fig. 28.1a, b).

Phase 0 (Rapid Depolarization)

In this phase, rapid inward movement of Na^+ occurs due to the opening of voltage-gated sodium channels (Na_v). This leads to variation in resting membrane potential from -90 to $+15$ mV.

Phase 1 (Initial Rapid Repolarization)

This phase leads to inactivation of sodium channels and influx of Cl^- .

Phase 2 (Plateau Phase)

In this phase, there is slow but prolonged opening of voltage-gated calcium channels; it brings about contraction.

Phase 3 (Repolarization)

In this phase, closure of calcium channels is initiated and K^+ efflux starts through potassium channels. In addition, inactivated sodium channels return to resting phase.

Phase 4 (Diastole)

This phase leads to restoration of ionic concentrations by Na^+/K^+ -activated ATPase (adenosine triphosphatase) and, finally, restoration of resting potential.

Important Electrocardiographic Parameters

- P wave represents atrial depolarization.
- PR interval equals the delay of conduction through the atrioventricular (AV) node.
- QRS complex represents ventricular depolarization.
- T wave represents ventricular repolarization.
- QT interval equals duration of AP in the ventricle (Fig. 28.1c).

Classification of Arrhythmia

Automaticity is the property of cardiac cells to generate spontaneous APs. The SA node normally displays the highest intrinsic rate. All other pacemakers are referred to as subsidiary or latent pacemakers because they take over the function of initiating excitation of the heart only when the SA node is unable to generate impulses or when these impulses fail to propagate.

Abnormal automaticity includes both reduced automaticity, which causes bradycardia, and increased automaticity, which causes tachycardia. Arrhythmias caused by abnormal automaticity can result from diverse mechanisms.

Researchers have shown many schemes to classify the mechanisms of cardiac arrhythmias (Fig. 28.2). Conventionally, these have been divided into nonreentrant and reentrant activity. However, mechanism of arrhythmias can also be classified on the basis of its origin and occurrence at the cellular and tissue levels. Another classification, based on dynamics and focused on the trigger-tissue substrate interactions, divided arrhythmogenic mechanisms into reduced and excess along with unstable calcium cycling.

Vivek Jain, M Pharm, PhD (Pharmacology)
Assistant Professor
Department of Pharmaceutical Sciences
Mohanlal Sukhadia University
Udaipur, Rajasthan

Yogesh A. Kulkarni, PhD
Associate Dean
Pharmaceutical Sciences
Shrihamben Pratabhai Patel School of Pharmacy &
Technology Management
SVKM's NMIMS
Mumbai, Maharashtra